On September 13th, Beigene (BGNE.US) rose 1.9% pre-market to $200. The State Council Information Office held a series of themed press conferences on "Promoting High-Quality Development" today. Li Li, the director of the National Medical Products Administration, introduced that the NMPA is accelerating the evaluation and approval of urgently needed clinical products, and will include eligible products in the priority evaluation and approval process. The time limit for the evaluation and approval of innovative drug clinical trials will be shortened from 60 working days to 30 working days.
美股异动丨百济神州盘前涨近2% 国家药监局加快临床药品审批
Beigene's stock rose nearly 2% pre-market as the National Medical Products Administration accelerated the approval of clinical pharmaceuticals.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated